Accès ouvert
2026
conference-abstract
OpenAlex
Natalia Soledad Tissera, Sharela Vega, José María Ucha, Sofía Llorente et autres
4206 Background: A subset of pancreatic cancer (PC) patients exhibits progressive disease (PD) as the best response to both first- and second-line chemotherapy (PD-PD), representing an ultra-refractory population with dismal outcomes. This group remains poorly characterized, highlighting a critical unmet need for …
es, ar, us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Sofía Llorente, Ángela Lamarca, Tian V. Tian
In a recent issue of The New England Journal of Medicine , an international team reported the final results of the Phase 2 eNRGy trial (NCT02912949), which evaluated the efficacy and safety of zenocutuzumab, a bispecific antibody against epidermal growth factor receptors …
es
(code pays fourni par la source)
2024
conference-abstract
OpenAlex
M. Yáñez, Enrique Javier Arenas, Teresa Mercade Macarulla, Tian Tian et autres
Abstract To conduct successful translational research for pancreatic ductal adenocarcinoma (PDAC), it is imperative to have preclinical models that accurately reflect the intricate molecular, genomic, and histological features of the disease. Patient-derived xenografts (PDXs) have emerged as invaluable platforms for studying tumor …
es
(code pays fourni par la source)